title: Suppression of dexamethasone-induced metallothionein expression and cis-diamminedichloroplatinum(II) resistance by v-mos.
abstract: Metallothionein has been implicated in resistance to anticancer drugs. We examined whether transient induction of metallothionein by dexamethasone causes resistance to cis-diamminedichloroplatinum(II) (cis-DDP) in malignant and nonmalignant cells. Normal rat kidney cells (6m2) were infected with a modified v-mos oncogene construct in which expression of v-mos and consequently transformation was temperature-sensitive occurring at the permissive temperature of less than 33 degrees C and not at the nonpermissive temperature of 37 degrees C. Temperature-sensitive oncogenic transformation by v-mos attenuated induction of metallothionein by dexamethasone. No induction of metallothionein was observed in a revertant 6m2 cell line (54-5A4), which expressed v-mos and was transformed at 37 degrees C. Only nontransformed 6m2 cells displayed resistance to cis-DDP after dexamethasone pretreatment for 24 h. Dexamethasone pretreatment did not cause marked resistance to doxorubicin or melphalan in nontransformed 6m2 cells. When 6m2 cells (37 degrees C) were pretreated with dexamethasone (0.5 microM) for 24 h and then incubated in dexamethasone-free medium for 24 h, both metallothionein levels and resistance to cis-DDP decreased significantly. Thus, transient resistance to cis-DDP can be produced by a nonmetal inducer of metallothionein in nontransformed cells. Glucocorticoid-induced protection is suppressed in cells expressing v-mos and this might form the basis of future strategies to improve the therapeutic index of cis-DDP.
authors.affiliation: Department of Pharmacology, University of Pittsburgh School of Medicine, Pennsylvania 15261.
authors.forename: A
authors.initials: A
authors.lastname: Basu
authors.forename: J S
authors.initials: JS
authors.lastname: Lazo
mesh_terms: D000818:Animals; D002471:Cell Transformation, Neoplastic / Q000139:chemically induced / Q000235:genetics* / Q000378:metabolism; D003907:Dexamethasone / Q000037:antagonists & inhibitors*; D004351:Drug Resistance; D007668:Kidney / Q000187:drug effects / Q000378:metabolism*; D008668:Metallothionein / Q000096:biosynthesis*; D017232:Oncogene Proteins v-mos; D009944:Organoplatinum Compounds / Q000037:antagonists & inhibitors / Q000378:metabolism*; D051381:Rats; D015682:Retroviridae Proteins, Oncogenic / Q000187:drug effects / Q000235:genetics*
chemical_list: D017232:Oncogene Proteins v-mos; D009944:Organoplatinum Compounds; D015682:Retroviridae Proteins, Oncogenic; C055423:didimethylsulfoxide dichloroplatinum(II); D003907:Dexamethasone; D008668:Metallothionein